Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

0.3159 +0.0100 (+3.27%)
Streaming Delayed Price Updated: 3:55 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
From SciSparc Ltd
Via GlobeNewswire
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
SciSparc Adopts Limited Duration Shareholder Rights Plan
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
From SciSparc Ltd
Via GlobeNewswire
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
From SciSparc Ltd
Via GlobeNewswire
SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
From SciSparc Ltd
Via GlobeNewswire
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
From SciSparc Ltd
Via GlobeNewswire
Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC)
Via ACCESSWIRE
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted European Patent for its Core Technology
From SciSparc Ltd
Via GlobeNewswire
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces 1-for-26 Reverse Share Split
From SciSparc Ltd
Via GlobeNewswire
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
From SciSparc Ltd
Via GlobeNewswire
Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC)
Via ACCESSWIRE
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
From SciSparc Ltd
Via GlobeNewswire
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.